Initial experience of pacing with a lumenless lead system in patients with congenital heart disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Bristol Congenital Cardiac Centre, Bristol Royal Hospital for Children and Bristol Royal Infirmary, Bristol, UK
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      BACKGROUND: Long-term pacing is frequently necessary in patients with congenital heart disease (CHD). Preservation of ventricular function and avoidance of venous occlusion is important in these patients. Site-selective pacing with a smaller diameter lead is achievable with the model 3830 lead (SelectSecure, Medtronic Inc., Minneapolis, MN, USA), which was specifically designed to target these complications. We describe our initial experience with the Model 3830 lead in patients with CHD. METHODS: Retrospective analysis of all patients undergoing site-selective implantation of a Model 3830 lead(s) from two congenital heart centers (Bristol, UK, and Dublin, Ireland) from October 2004 until February 2008. RESULTS: We implanted 139 SelectSecure leads (atrial n=70; ventricular n=69) in 90 patients (57 male) with CHD. Median age at implantation: 13.4 years (1.1-59.2 years), median weight: 43 kg. Sixty-nine patients (76%) were children (<18 years). Indications for lead implantation included atrioventricular block (n=55), sinus node disease (n=18), implantable cardiac defibrillator (n=12), antitachycardia pacing (n=4), and cardiac resynchronization (n=1). Twenty-two patients underwent pre-existing lead extraction during the same procedure. All the attempted procedures resulted in successful pacing. One patient had a significantly raised threshold at implantation. There was no procedural mortality. There were two procedural complications. Three patients required lead repositioning for increasing thresholds early postprocedure (<6 weeks). Four leads (2.9%) had displaced on median follow-up of 21.8 months (0.5-42 months). CONCLUSIONS: The Model 3830 lead is safe and effective in patients with CHD. This is a technically challenging patient group yet procedural complication and lead displacement rates are acceptable.
    • Journal Subset:
      Allied Health; Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA
    • ISSN:
      0147-8389
    • MEDLINE Info:
      PMID: NLM19769583 NLM UID: 7803944
    • Publication Date:
      20100101
    • Publication Date:
      20150711
    • Accession Number:
      http://dx.doi.org/10.1111/j.1540-8159.2009.02487.x
    • Accession Number:
      105235432
  • Citations
    • ABNT:
      CHAKRABARTI S et al. Initial experience of pacing with a lumenless lead system in patients with congenital heart disease. Pacing & Clinical Electrophysiology, [s. l.], v. 32, n. 11, p. 1428–1433, 2009. DOI 10.1111/j.1540-8159.2009.02487.x. Disponível em: http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=ccm&AN=105235432&authtype=sso&custid=s5834912. Acesso em: 23 fev. 2020.
    • AMA:
      Chakrabarti S, Morgan GJ, Kenny D, et al. Initial experience of pacing with a lumenless lead system in patients with congenital heart disease. Pacing & Clinical Electrophysiology. 2009;32(11):1428-1433. doi:10.1111/j.1540-8159.2009.02487.x.
    • APA:
      Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin RP, Turner MS, & Stuart AG. (2009). Initial experience of pacing with a lumenless lead system in patients with congenital heart disease. Pacing & Clinical Electrophysiology, 32(11), 1428–1433. https://doi.org/10.1111/j.1540-8159.2009.02487.x
    • Chicago/Turabian: Author-Date:
      Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin RP, Turner MS, and Stuart AG. 2009. “Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease.” Pacing & Clinical Electrophysiology 32 (11): 1428–33. doi:10.1111/j.1540-8159.2009.02487.x.
    • Harvard:
      Chakrabarti S et al. (2009) ‘Initial experience of pacing with a lumenless lead system in patients with congenital heart disease’, Pacing & Clinical Electrophysiology, 32(11), pp. 1428–1433. doi: 10.1111/j.1540-8159.2009.02487.x.
    • Harvard: Australian:
      Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin RP, Turner MS & Stuart AG 2009, ‘Initial experience of pacing with a lumenless lead system in patients with congenital heart disease’, Pacing & Clinical Electrophysiology, vol. 32, no. 11, pp. 1428–1433, viewed 23 February 2020, .
    • MLA:
      Chakrabarti S, et al. “Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease.” Pacing & Clinical Electrophysiology, vol. 32, no. 11, Nov. 2009, pp. 1428–1433. EBSCOhost, doi:10.1111/j.1540-8159.2009.02487.x.
    • Chicago/Turabian: Humanities:
      Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin RP, Turner MS, and Stuart AG. “Initial Experience of Pacing with a Lumenless Lead System in Patients with Congenital Heart Disease.” Pacing & Clinical Electrophysiology 32, no. 11 (November 2009): 1428–33. doi:10.1111/j.1540-8159.2009.02487.x.
    • Vancouver/ICMJE:
      Chakrabarti S, Morgan GJ, Kenny D, Walsh KP, Oslizlok P, Martin RP, et al. Initial experience of pacing with a lumenless lead system in patients with congenital heart disease. Pacing & Clinical Electrophysiology [Internet]. 2009 Nov [cited 2020 Feb 23];32(11):1428–33. Available from: http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=ccm&AN=105235432&authtype=sso&custid=s5834912